EverSource Wealth Advisors LLC grew its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 34.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 9,620 shares of the company’s stock after buying an additional 2,491 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $8,848,000 as of its most recent filing with the SEC.
Other large investors have also recently made changes to their positions in the company. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $25,000. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $30,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares during the last quarter. Finally, Dorato Capital Management acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $36,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Key Headlines Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Analysts and investors remain optimistic about Lilly’s earnings momentum. The company generated $19.8 billion in first-quarter revenue, up roughly 55.5% year over year, and recent analyst price targets have generally exceeded the current trading level. The median target from 14 analysts is $1,336, with targets as high as $1,500. Eli Lilly Stock Opinions on Growth and AI Ventures
- Positive Sentiment: Lilly’s expanding oncology and newer-medicine portfolio is expected to contribute meaningfully to second-quarter results, supplementing demand for its GLP-1 franchise. This diversification could reduce reliance on weight-loss and diabetes products while supporting long-term revenue growth. Here’s How LLY’s Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
- Positive Sentiment: The company is making a reported $2.8 billion investment aimed at expanding growth beyond GLP-1 drugs. Investors also highlighted Lilly’s investments in artificial-intelligence drug discovery, data infrastructure and potential opportunities in emerging treatment categories. Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
- Neutral Sentiment: Institutional trading was mixed: 2,169 investors added shares in the latest quarter, while 1,653 reduced positions. Several large holders made sizable sales, offset by substantial purchases from other institutions. Social-media commentary also emphasized Lilly’s revenue scale and sustained earnings power, but these discussions are not formal company guidance. Eli Lilly Stock Opinions on Growth and AI Ventures
- Negative Sentiment: Insider activity included one reported open-market sale by an executive involving 2,500 shares. While the transaction is relatively small compared with Lilly’s market value, it provides a modest counterpoint to the otherwise bullish coverage. Eli Lilly Stock Opinions on Growth and AI Ventures
Eli Lilly and Company Stock Performance
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 35.03 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the company. Truist Financial increased their price objective on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Guggenheim boosted their target price on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Finally, Rothschild & Co Redburn boosted their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.
Check Out Our Latest Stock Report on LLY
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Read More
- Five stocks we like better than Eli Lilly and Company
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
